Insights

Public Offering Success CG Oncology demonstrated a successful initial public offering by raising $437 million in gross proceeds with 23 million shares sold at $19 each. This financial feat signifies investor confidence and potential growth opportunities for the company.

Research Fellowship Recognition The receipt of the Non-Muscle Invasive Bladder Cancer Research Fellowship Award showcases CG Oncology's commitment to advancing bladder cancer research. This recognition can open doors for collaborations and partnerships in the medical and research communities.

Investment Interest Polar Asset Management Partners Inc. made a substantial investment of $973,000 in CG Oncology, indicating external confidence in the company's innovative therapies. Such investments can pave the way for strategic alliances and business growth.

Interim Data Showcase CG Oncology's release of promising interim data from the Phase III BOND-003 study highlights the efficacy of cretostimogene immunotherapy in treating non-muscle invasive bladder cancer. This data can attract healthcare providers and pharmaceutical companies seeking groundbreaking treatment options.

Financial Endorsement The successful financing of $380 million in the initial public offering reinforces CG Oncology's solid financial standing and potential for market expansion. This achievement can capture the attention of investors and stakeholders looking for promising biotech ventures.

CG Oncology Tech Stack

CG Oncology uses 8 technology products and services including QuickBooks, WordPress, Genesys, and more. Explore CG Oncology's tech stack below.

  • QuickBooks
    Accounting And Finance
  • WordPress
    Content Management System
  • Genesys
    Customer Experience Management
  • SAP
    Customer Relationship Management
  • Open Graph
    Miscellaneous
  • Priority Hints
    Performance
  • ZURB Foundation
    UI Frameworks
  • Minitab
    Visualisation Software

Media & News

CG Oncology's Email Address Formats

CG Oncology uses at least 1 format(s):
CG Oncology Email FormatsExamplePercentage
First.Last@cgoncology.comJohn.Doe@cgoncology.com
49%
Last@cgoncology.comDoe@cgoncology.com
2%
First.Last@cgoncology.comJohn.Doe@cgoncology.com
49%

Frequently Asked Questions

Where is CG Oncology's headquarters located?

Minus sign iconPlus sign icon
CG Oncology's main headquarters is located at 400 Spectrum Center Drive Suite 2040 Irvine, CA 92618 US. The company has employees across 5 continents, including North AmericaAsiaAfrica.

What is CG Oncology's phone number?

Minus sign iconPlus sign icon
You can contact CG Oncology's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is CG Oncology's stock symbol?

Minus sign iconPlus sign icon
CG Oncology is a publicly traded company; the company's stock symbol is CGON.

What is CG Oncology's official website and social media links?

Minus sign iconPlus sign icon
CG Oncology's official website is cgoncology.com and has social profiles on LinkedIn.

How much revenue does CG Oncology generate?

Minus sign iconPlus sign icon
As of February 2025, CG Oncology's annual revenue reached $35M.

What is CG Oncology's SIC code NAICS code?

Minus sign iconPlus sign icon
CG Oncology's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does CG Oncology have currently?

Minus sign iconPlus sign icon
As of February 2025, CG Oncology has approximately 130 employees across 5 continents, including North AmericaAsiaAfrica. Key team members include Chief Financial Officer: C. R.Chief Medical Officer: V. K.Chief Technical Officer: S. B.. Explore CG Oncology's employee directory with LeadIQ.

What industry does CG Oncology belong to?

Minus sign iconPlus sign icon
CG Oncology operates in the Biotechnology Research industry.

What technology does CG Oncology use?

Minus sign iconPlus sign icon
CG Oncology's tech stack includes QuickBooksWordPressGenesysSAPOpen GraphPriority HintsZURB FoundationMinitab.

What is CG Oncology's email format?

Minus sign iconPlus sign icon
CG Oncology's email format typically follows the pattern of . Find more CG Oncology email formats with LeadIQ.

How much funding has CG Oncology raised to date?

Minus sign iconPlus sign icon
As of February 2025, CG Oncology has raised $238M in funding. The last funding round occurred on Dec 12, 2024 for $238M.

When was CG Oncology founded?

Minus sign iconPlus sign icon
CG Oncology was founded in 2010.
CG Oncology

CG Oncology

Biotechnology ResearchCalifornia, United States51-200 Employees

CG Oncology, Inc. (Nasdaq: CGON), is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative oncolytic immunotherapies to live with dignity and have an enhanced quality of life.

Our lead candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. Cretostimogene grenadenorepvec is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with cretostimogene grenadenorepvec in combination with OPDIVO® (nivolumab).

Section iconCompany Overview

Headquarters
400 Spectrum Center Drive Suite 2040 Irvine, CA 92618 US
Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
CGON
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2010
Employees
51-200

Section iconFunding & Financials

  • $238M

    CG Oncology has raised a total of $238M of funding over 8 rounds. Their latest funding round was raised on Dec 12, 2024 in the amount of $238M.

  • $10M$50M

    CG Oncology's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $238M

    CG Oncology has raised a total of $238M of funding over 8 rounds. Their latest funding round was raised on Dec 12, 2024 in the amount of $238M.

  • $10M$50M

    CG Oncology's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.